Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L01CE01

Hycamtin(topotecan)

Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma

Marketing Authorisation Holder: Sandoz Pharmaceuticals d.d.

EMA Authorisation: 12/11/1996

INN: topotecan

Indication

Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Hycamtin — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.